Find Faculty

Sundar Jagannath, MBBS

img_Sundar Jagannath
PROFESSOR | Medicine, Hematology and Medical Oncology
212-241-7873
Are you a patient?
View my
Provider Profile
Specialties
Internal Medicine, Cancer (Oncology)

MD, University of Baroda

Residency, Internal Medicine, Bronx-Lebanon Hospital Center

Residency, Internal Medicine, BronxCare Hospital Center

Residency, Internal Medicine, Wayne State University

Residency, Medical Oncology, University of Texas MD Anderson Cancer Center

Certifications

American Board of Internal Medicine
444
Publications

Selected Publications

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma. Shaji Kumar, Sundar Jagannath, Katja C. Weisel, Laura Rosiñol, Xavier Leleu, Meletios Athanasios Dimopoulos, Efstathios Kastritis, David S. Siegel, Jorge Monge, Juan Du, Javier de la Rubia, Pedro Asensi Cantó, Jae Hoon Lee, María Victoria Mateos, Borja Puertas, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Blade, Shuji Ozaki, Meral Beksac, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Nicolle Bonar, Paul Spin, Mostafa Shokoohi, Muhaimen Siddiqui, Di Wang, Kevin Hou, Michael E.D. West, Christian Hampp, Jeannette Green, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel E. Sobel, Jessica J. Jalbert, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Brian G.M. Durie. Blood Cancer Journal

Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma. Darren Pan, Tarek H. Mouhieddine, Tianxiang Sheng, Weijia Fu, Erin Moshier, Joshua Richter, Samir Parekh, Sundar Jagannath, Ajai Chari, Adriana C. Rossi, Larysa J. Sanchez, Santiago Thibaud, Cesar Rodriguez, Hearn J. Cho, Shambavi Richard. Bone Marrow Transplantation

Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Melissa Alsina, Nina Shah, Sundar Jagannath, Jonathan L. Kaufman, David Siegel, Nikhil C. Munshi, Jacalyn Rosenblatt, Yi Lin, Andrzej J. Jakubowiak, Benjamin A. Derman, Aojun Li, Pingping Mao, Maeva Fincker, Ashish Yeri, Nathan Martin, Timothy B. Campbell, Olivia Finney, Anna Truppel-Hartmann, Fabio Petrocca, Jesus G. Berdeja, Noopur Raje. Cancer Immunology Research

View All Publications

One Gustave L. Levy Place

Box 1185

New York, NY 10029

212-241-7873

Residential Tower Floor 6th

10 E 102nd St

New York, NY 10029

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Jagannath during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Genentech, Inc.
  • GSK plc.
  • Caribou Biosciences, Inc.
  • Takeda Pharmaceuticals Of North America, Inc.
  • Bristol-Meyers Company
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi US Services Inc.
  • Janssen Services LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.